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Summary 
Objective: There is an increasing evidence that genetic factors play a role in the etiology of malignant tumors.
Mutations of BRCA1 and BRCA2 genes are responsible for an increased risk of ovarian cancer. 
The role of mutations in NOD2 gene in this type of neoplasm is still under investigation. 
The aim: The aim of this study was to determine:
1. incidence of NOD 2 3020insC constitutional mutation in a group of consecutive women with ovarian cancer,
2. risk of developing ovarian cancer in patients with NOD2 gene mutation,  
3. clinical and pathological features of ovarian cancer in NOD2 gene mutation carriers.  
Patients and Methods: Clinical and pathological data were collected from 257 non-selected patients with primary
epithelial ovarian cancer. The researches identified NOD2 3020insC gene mutation. On the basis of patient source
documentation we obtained the data concerning the age of patients at diagnosis, histopathological recognition,
FIGO stage and morphological grade G.
Results: 19 out of 257 women were identified with germ-line 3020insC mutation of NOD2 gene (7.39%). An
increased risk of ovarian cancer in NOD2 mutation carriers was not revealed (OR=1.01; p=0.928; 95%CI=0.61-
1.66). The mean age at diagnosis of patients with NOD2 mutation was 54.8 (SD=9.9), while for non-carriers it was
53.2 (SD=10.2). The difference between these frequencies was statistically irrelevant (p=0.550). 
Clinical and pathological profile of ovarian cancer was made. We assessed the following features: age at disease
onset, histopathology, FIGO stage and morphological grade G. For NOD2 mutation carriers no statistically signifi-
cant features of ovarian cancer were revealed.
Conclusion:
1. Despite high frequency of constitutional mutations occurrence in NOD2 gene in women with ovarian cancer,
genetic testing seem not to be justified in all women diagnosed with this disease.
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Introduction
Ovarian cancer is a major women’s health problem in
gynecologic oncology. So far, the analyses have shown poor
efficiency of screening procedures in decreasing mortality
rates from this disease. A hope is put on indicating women
with an increased risk of this neoplasm. It has been assessed,
that technological progress in molecular research will certain-
ly lead to the development of quick tests, which will enable
detecting mutations in patients and their families. Finding
mutation carriers in families with ovarian cancer may be of
great importance in prevention of this disease. 
It is claimed, that the leading cause of high genetic predis-
position towards ovarian cancer is carrying of mutations in
constitutional genes BRCA1 and BRCA2. However, it has
been observed, that in many cases of familial incidence, the
genetic cause of this neoplasm is unknown. This provoked
further research into other genes like NOD2, whose mutations
or polymorphism variants are responsible for an increased risk
of this disease.
In order to broaden our knowledge about ovarian cancer
it is extremely important to determine the incidence of genet-
ic disturbances as well as clinical and pathological features of
this disease in mutation carriers. It is also crucial to appoint
families with an increased risk of ovarian cancer by doing tests
for genetic disturbance carrier state and by analysing pedigree
and clinical data of each patient. Some data suggest also a
relationship between the mutation incidence and sensitivity to
cytostatics.
The NOD2 gene was identified and mapped on chromo-
some 16q12 by Hugot et al. [1]. 
It consists of 12 exons and codes cytoplasmatic protein
composed of 1040 aminoacids. The NOD2 protein has three
functional domains: EBD (amino-terminal effector-binding
domain) with two CARDs (caspase –recruitment domain), a
centrally placed NOD (nucleotide-binding oligomerization
domain) and LRD (carboxy-thermal ligand-recognition
domain) which includes 10 leucine repeats (LRRs) on the car-
boxy therm [2].
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2. Due to a lack of increased risk of ovarian cancer in NOD2 gene mutation carriers, proceedings for them may not
differ from recommendations for general population.
3. It is difficult to determine characteristic clinical and pathological features of ovarian cancer for NOD2 gene muta-
tion carriers.
Key words: ovarian cancer / NOD2 /
Streszczenie 
Wst´p: Obserwuje si´ coraz wi´cej dowodów na rol´ czynników genetycznych w rozwoju nowotworów. 
Wiadomo, ˝e mutacje w genie BRCA1 i BRCA2 odpowiadajà za podwy˝szone ryzyko rozwoju raka jajnika. 
Znaczenie innych zaburzeƒ genetycznych takich jak mutacje w genie NOD2 jest ciàgle jeszcze badane. 
Cel pracy: Celem badania by∏o okreÊlenie:
1. cz´stoÊci wyst´powania mutacji konstytucyjnej NOD2 3020insC w grupie nieselekcjonowanych kobiet z rakiem
jajnika,
2. ryzyka rozwoju raka jajnika u pacjentek z mutacjà genu NOD2,
3. cech patologiczno-klinicznych raka jajnika u nosicielek mutacji NOD2. 
Materia∏ i metoda: Do badania w∏àczono 257 nieselekcjonowane chore z rakiem jajnika. Wykonano oznaczenia
mutacji 3020insC w genie NOD2. 
Zebrano dane z historii chorób dotyczàce wieku zachorowania, rozpoznania histopatologicznego, stopnia kliniczne-
go zaawansowania nowotworu wg FIGO i stopnia morfologicznej z∏oÊliwoÊci G. 
Wyniki: Mutacj´ 3020insC w genie NOD2 badano u 257 pacjentek. Zmian´ wykryto u 19 kobiet uzyskujàc cz´stoÊç
7,39%. Nie wykazano podwy˝szenia ryzyka rozwoju raka jajnika dla nosicielek mutacji NOD2 (OR=1,01;
95%CI=0,61-1,66; p=0,928). Ârednia wieku zachorowania dla nosicielek mutacji NOD2 wynosi∏a 54,8 (SD=9,9) w
porównaniu do 53,2 (SD=10,2) dla chorych bez mutacji. Ró˝nica cz´stoÊci nie by∏a istotna statystycznie (p=0,550).
Dokonano charakterystyki patologiczno-klinicznej raka jajnika. Ocenie poddano wiek zachorowania, typ histologicz-
ny nowotworu, stopieƒ morfologicznej z∏oÊliwoÊci G i stopieƒ zaawansowania wg FIGO.  
Nie znaleziono istotnych statystycznie cech nowotworu charakterystycznych dla nosicielek mutacji w genie NOD2.
Wnioski:
1. Pomimo wysokiej cz´stoÊci wyst´powania mutacji konstytucyjnych w genie NOD2 w grupie kobiet chorych na
raka jajnika nie wydaje si´ zasadne wykonywanie testu u wszystkich chorych z tym nowotworem. 
2. Z powodu braku podwy˝szonego ryzyka rozwoju raka jajnika u nosicielek mutacji w genie NOD2 post´powanie
w stosunku do nich mo˝e nie odbiegaç od rekomendacji dla populacji ogólnej. 
3. Trudno jest okreÊliç charakterystyczne cechy patologiczno-kliniczne raka jajnika dla nosicielek mutacji NOD2. 
S∏owa kluczowe: rak jajnika / NOD2 /
The NOD2 protein is involved in inflammatory response
and activation of nuclear factor kappa-B (NFκB) through
interactions with CARD domains after stimulation of mono-
cytes by bacterial products [3]. The NOD2 protein recognises
muramyl dipeptide (MDP) deriving from bacterial peptido-
glygan (PGN) through LRRs and additionally activates
NFκB through the connection of CARDs with an adequate
CARD from Rip2/RICK/CARDIAK [4]. The analysis of
NOD2 evolution has shown strong conservatism of the
encoded protein, which is similar from 44.5% in fugu fish pro-
tein to 99.1% in chimpanzee [5].
The activation of NFκB is stronger if 3020insC mutation
occurs in NOD2. Insertion of cytosine in exon 11 causes a
frameshift and, consequently, substitution of leucine in the
position 1007 (Leu1007fsinsC) in NOD2 protein. This muta-
tion, due to premature termination of protein synthesis, leads
to 33 aminoacids shortening in the protein sequence. 
In a number of surveys it was observed, that mutations in
NOD2 gene are connected with a predisposition to Crohn’s
disease. People suffering from this disease have shown an
increased risk of colon cancer. However, it is still to explain
how exactly the neoplasm develops. It is suggested, that genes
involved in inflammatory response such as INFγ and TNFα
cause neutrophile activation, which generates significant
amount of free oxygen radicals [6]. It is thought that long-
term exposition of gastrointestinal tract epithelium to free
oxygen radicals may be related to an increased mutation inci-
dence and, in consequence, susceptibility to develop neo-
plasms.
Not only patients with Crohn’s disease have an increased
NFκB activity level. This factor also plays a role in chronic
pulmonary diseases and lung cancer development in smokers
[7]. It has been proven that cytokines which cause an increase
of NFκB level lead to ovarian cancer cells growth and that
inhibition of NFκB activity may suppress this growth [8, 9].
The aim
The aim of this study was to determine:
1. Incidence of NOD2 3020insC constitutional mutation
in a group of consecutive women with ovarian cancer.
2. Risk of developing ovarian cancer in patients with
NOD2 gene mutation.
3. Clinical and pathological features of ovarian cancer in
NOD2 gene mutation carriers.  
Material and methods 
The focus group consisted of 257 women with ovarian
cancer treated  at the Division of Gynecologic Oncology, Poz-
naƒ University of Medical Sciences in the years 2003 - 2006.   
Each patient signed informed consent before venous blood
collection for a genetic test. The aim of the test was to detect
3020insC mutation in NOD2 gene. Genomic DNA was isolat-
ed from peripheral blood leucocytes. Analyses were performed
in the Department of Genetics and Pathology –International
Hereditary Cancer Center, Pomeranian Medical University,
Szczecin. Blood samples were stored until analyses were done.
The data collected from patient source documentation includ-
ed: age at diagnosis, pathological recognition, FIGO stage and
morphological grade G. 
Statistic methods
For statistic analyses STATISTICA v. 7.0 from StatSoft
and Microsoft Excel were used. Verification of a relationship
between the two qualitative features was carried by means of
the Chi2 test, alternatively with Yates correction. The U
Mann-Whitney test was used to compare age distribution in
patient groups. The outcome was recognized as statistically
significant when p<0.05. Odds ratio (OR) and 95%CI for OR
were calculated by means of MS Excel function. 
Methods of mutation detection 
The incidence of each mutation was also determined for a
control group from the Polish population. Genetic tests were
done by researches from the Department of Genetics and
Pathology – Hereditary Cancer Center in Szczecin [10]. 
It has been assessed, that 3020insC mutation in NOD2
gene occurred in 140/1910 women from this group (7.32%). 
Methods of mutation detection in NOD2 gene
Genomic DNA was extracted from peripheral blood
leukocytes by the standard method with proteinase K. Molec-
ular investigations of 3020insC mutations were carried out by
an allele-specific PCR assay using a standard kit (patent no. P-
364412, Poland).
For genomic DNA amplification by means of PCR,
primers framing the basic region 533 which surrounds
3020insC alleles were applied. Each PCR reaction included
two additional primers. The first was to detect the wild allele
and the second to recognize 3020insC allele. 
For exposure purposes 5µl of PCR product was put to the
electrophoresis on 1.5% agar gel stabilised with etidine bro-
mide (Seatem FMC, buffer 1X TBE, 25µg/ml etidine bromide)
at the voltage 6V/cm for 30 minutes. Separated products were
exposed in UV light.
Results
The test for 3020insC mutation in NOD2 gene was done in
257 patients. The mutation was detected in 19 women, reach-
ing the incidence 7,39%. An increased risk of ovarian cancer
for NOD2 mutation carriers was not revealed (OR=1.01;
95%CI=0.61-1.66; p=0.928). 
The mean age at diagnosis was 54,8 (SD=9.9) for NOD2
mutation carriers of and 53.2 (SD=10,2) for patients without
this mutation. The difference in occurrence frequency was sta-
tistically insignificant (p=0.550).
Clinical and pathological features of ovarian cancer were
described. The collected data included: age at diagnosis,
pathological recognition, FIGO stage and morphological
grade G.  
The age at diagnosis was analyzed as a feature in the stud-
ied group. Statistic significance was revealed neither for muta-
tion carriers aged ≤50 years (OR=0.74; 95%CI=0.28-1.94;
p=0.538) nor >50 years (OR=1.35; 95%CI=0.51-3.56;
p=0.538). 
Histological type of ovarian cancer was analyzed as a fea-
ture in the studied group. 
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No characteristic histological type was found in carriers of
the mutation. Statistic significance was not revealed for any
type of ovarian cancer. Thus, for adenocarcinoma serosum
(OR=0.62; 95%CI=0.24-1.64; p=0.335), for adenocarcinoma
endometrioides (OR=1.88; 95%CI=0.64-5.53; p=0.245) and
for adenocarcinoma solidum (OR=1.40; 95%CI=0.44-4.46;
p=0.564). 
Morphological grade G of ovarian cancer was analyzed in
the studied group. No statistic significance was revealed for
any morphological stage in mutation carriers.
It was assessed as follows: G1 (OR=1.02; 95%CI=0.31-
3.33; p=0.980), G2 (OR=0.74; 95%CI=0.24-2.25; p=0.595)
and G3 (OR=1.33; 95%CI=0.46-3.90; p=0.599).
FIGO stage was analyzed in the studied group. No char-
acteristic feature was found for carriers of 3020insC mutation
in NOD2 gene. The estimation was made for stage I
(OR=1.08; 95%CI=0.37-3.14; p=0.822), for stages I/II togeth-
er (OR=1.24; 95%CI=0.47-3.28; p=0.660) as well as for stages
III/IV together (OR=0.80; 95%CI=0.30-2.12; p=0.660).
Discussion
In a number of surveys it has been observed that muta-
tions in NOD2 gene are connected with predisposition to
Crohn’s disease. Researchers continuously have been interest-
ed in the role of chronic inflammation in carcinogenesis.
According to the recent studies, patients with this disease have
an increased risk of colon cancer as well as of other neo-
plasms. 
In the focus group of 257 patients we looked for 3020insC
mutation. This genetic change was revealed in 19 women
(7.39%). Thus an increased risk of ovarian cancer was not
proved for this mutation (OR=1.01; 95%CI=0.61-1.66;
p=0.928). 
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Table I. Age at diagnosis for carriers of 3020insC mutation of
NOD2 gene in the group of patients with ovarian cancer. 
Table III. Morphological grade – G of ovarian cancer in carriers of
3020insC mutation in NOD2 gene.
Table IV. FIGO stage in carriers of 3020insC mutation in NOD2
gene in the group of patients with ovarian cancer. 
Table II. Histological type of ovarian cancer in carriers of 3020insC
mutation in NOD2 gene.
However, in the light of the results obtained in the pre-
sented study, it is worth to recall the outcome of the study by
Lubiƒski et al, which showed statistically significant increase
of ovarian cancer risk (OR=1.6; p=0.03) [11]. In a group of
317 patients mutation carrying was found in 35 women (11%).
In our focus group the frequency of mutation carrying was
lower and not statistically significant.
There have been few studies concerning the relationship
between NOD2 mutation and ovarian cancer. Below we
would like to reckon some interesting results obtained in some
of them.
In the study by Lubiƒski et al. the relationship between
3020insC NOD2 mutation and neoplasms incidence was
assessed in a group of 2604 patients with neoplasms and in a
control group of 1910 people. The 3020insC NOD2 mutation
frequency in the group with neoplasms was higher in 8 out of
12 analyzed subgroups with different cancers. A significant
relationship was found for colon cancer (OR=1.8), especially
in the age group of >50 years (OR=2.2; p=0.006), for lung
cancer (OR=1.7) and for ovarian cancer (OR=1.6). An asso-
ciation with low stage larynx cancer was also observed in the
age group of <50 years (OR=2,9; p=0,009). 
No relationship was found between the studied mutation
and breast cancer in general however, the predisposition to
intraductal breast cancer (DCIS) was noticed (OR=2.1;
p=0.01). This relationship was especially distinct in women
aged <50 years with DCIS (OR=3.0; p=0.01). Also, an asso-
ciation between kidney cancer and NOD2 mutation was
found (OR=0.4; p=0.03). The control group at Lubiƒski et al.
study consisted of adults and newborns from five Polish cities.
The frequency of NOD2 3020insC mutation occurrence in the
group of newborns (7.8%) was similar to the group of adults
(6.9%). No statistic difference in mutation occurrence fre-
quency depending on the Polish cities was found. 
For the inhabitants of Szczecin the observed frequency
was 8.2%, while for other cities 7.3%. It may be explained by
small differences in ethnic background in the Polish popula-
tion compared to the societies of North America and Western
Europe. The homogenic ethnicity of Polish population has
already been proved in some research [12]. 
3020insC mutation is also present in other European pop-
ulations, so it is expected, that similar studies will be conduct-
ed in other countries. For example, in the Greek population a
research into colon cancer revealed an association with NOD2
[13]. However, there are exceptions. For instance, a Finnish
study proved no association between NOD2 mutation and
colon cancer [14].
To sum up, NOD2 mutations are quite common. In
Lubiƒski’s study 7.3% people from the control group are car-
riers. The study proves that carrying NOD2 3020insC muta-
tion causes 30% higher risk of developing neoplasms [15]. 
In the study by D´bniak et al. a correlation between the
NOD2 mutation and colon cancer was found (31/255; 12.2%;
OR=1.8; p=0.01), especially in an older age (OR=2.2). The
correlation was also found in: breast cancer (18/126; 14.3%),
DCIS (OR=2.1; p=0.009), kidney cancer (8/245; 3.2%;
OR=0.4; p=0.02); lung cancer (30/258; 11.6%; OR=1.7;
p=0.03) and ovarian cancer (35/317; 11.0%; OR=1.6; p=0.03)
[16]. 
No statistic significance was found for: urine bladder can-
cer (18/172; 10.5%; OR=1.5), larynx cancer (23/223; 3.2%;
OR=1.5), malignant melanoma (10/198; 5.1%; OR=0.7), pan-
creas cancer (6/127; 4.7%; OR=0.6), prostate cancer (17/298;
5.7%; OR=0.6), stomach cancer (20/213; 9.4%; OR=1.3) or
thyroid cancer (8/82; 9.8%; OR=1.4). In the control group of
1910 people 140 mutation carriers were revealed (7.3%). 
In the study by Janiszewska et al. carried on a group of
148 patients with breast cancer 3020insC mutation was found
in 8.8%. The mean age at disease was 43 years [17]. In the
group of patients older than 50, the mutation was not
revealed. The association between NOD2 mutation and the
familial breast cancer was also not proved. However, it was
observed that the mutation frequency was twice higher
(11.4%) in the group of women from families with sporadic
breast cancer and with aggregation of other neoplasms, espe-
cially in gastrointestinal tract. In 104 out of 148 examined
families (70.3%), a concentration of following cancers was
revealed: colon, pancreas, stomach, larynx, lung, ovarian,
endometrial, prostate, kidney, malignant melanoma, leukemia
and sarcoma.
Kurzawski et al. also observed an association between
Crohn’s disease and  NOD2 3020insC gene mutation carrying
in the group of 556 patients with colon cancer [18].
A significant relationship between age and cancer inci-
dence in general was not proved. In patients with larynx can-
cer in the study by Lubiƒski et al. the association was stronger
for young people, while in patients with colon cancer the rela-
tionship was stronger for the older than 50. In the group with
ovarian cancer for  NOD2 3020insC carriers no significance of
age at disease was observed.
What surprises, is an association of NOD2 mutation with
Crohn’s disease, as well as with other neoplasms. It should be
remembered that NOD2 penetration for Crohn’s disease inci-
dence amounted below 1%, while for colon cancer it was
about 10%. This is the reason why suggestion that NOD2
mutation does not cause evident predisposition to these dis-
eases was made.
In the study by Irmejs et al. NOD2 mutation incidence in
Latvia was assessed [19]. The NOD2 3020insC mutation was
present in 7.7% (18/235) patients with colon cancer, in 9.2%
(17/185) with breast cancer and in 7.7% (75/975) people from
an control group. The NOD2 3020insC mutation was associ-
ated with a higher risk of breast cancer (OR=2.5; p<0.05) for
patients diagnosed at the age between 51 and 60.
It has been thought, that NOD2 3020insC mutation car-
rying is responsible for higher risk of different neoplasms inci-
dence, including cancer of colon, lung, larynx and ovary. It
has been also assumed, that mutation carrying increases the
risk of cancer by 25-35%. 
However, a significant raise of the risk of any neoplasms
was not confirmed by further research. Consequently, there
are no genetic or clinical recommendations available. The
NOD2 gene is involved in inflammatory processes regulations,
but it is not obvious if suppression of control mechanisms is
responsible for higher cancer incidence.
Early diagnostics and neoplasm prevention procedures are
now a priority in the health care all over the world. Genetic
studies have an immense significance, as it is assumed that
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most of neoplasms have their genetic basis. Identification of
higher predisposition towards cancer gives a chance for effec-
tive treatment and higher survival rates. The research into
detection of inherited predisposition to cancer is focused on
discovering the incidence pattern related to genetic distur-
bances. Identification of people with higher cancer risk would
be more effective if databases and population registries were
implemented and used.
Conclusion
1. Despite high frequency of constitutional mutations occur-
rence in NOD2 gene in women with ovarian cancer, genet-
ic testing seem not to be justified in all women diagnosed
with this disease.
2. Due to lack of increased risk of ovarian cancer in NOD2
gene mutation carriers, proceedings for them may not dif-
fer from recommendations for general population.
3. It is difficult to determine characteristic clinical and patho-
logical features of ovarian cancer for NOD2 gene mutation
carriers.
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